drugset
drugset / Trial / NCT01448395

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104

NCT01448395 ↗

Phase 1 Completed 6 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelBasic science

Summary

A study to look at how radiolabelled NXL104 is taken up, broken down and removed by the body when given as an injection into the blood stream.

Timeline

Start
2011-10
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject avibactam Small molecule 500 mg Intravenous

Indications

No indication recorded.